Asciminib as a new option in the treatment of chronic myeloid leukemia

Future OncologyVol. 17, No. 36 EditorialAsciminib as a new option in the treatment of chronic myeloid leukemiaBetül İbiş, Mario Tiribelli & Ahmet Emre EşkazanBetül İbiş https://orcid.org/0000-0002-6148-6177Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey, Mario Tiribelli https://orcid.org/0000-0001-9449-2621Division of Hematology and Blood and Marrow Transplantation, Department of Medical Area, University of Udine, Udine, Italy & Ahmet Emre Eşkazan *Author for correspondence: Tel.: +90 533 722 7376; E-mail Address: emre.eskazan@iuc.edu.trhttps://orcid.org/0000-0001-9568-0894Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, TurkeyPublished Online:18 Nov 2021https://doi.org/10.2217/fon-2021-1174AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: ABL myristoyl pocketasciminibchronic myeloid leukemiaT315Ityrosine kinase inhibitorReferences1. Tiribelli M, Eskazan AE. Tyrosine kinase inhibitor sequencing in patients with chronic myeloid leukemia. Oncol. Ther. 7(2), 95–100 (2019).Crossref, Medline, Google Scholar2. Ibrahim AR, Paliompeis C, Bua M et al. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood 116(25), 5497–5500 (2010).Crossref, Medline, CAS, Google Scholar3. Ongoren S, Eskazan AE, Suzan V et al. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature. Hematology 23(4), 212–220 (2018).Crossref, Medline, CAS, Google Scholar4. Chan O, Talati C, Isenalumhe L et al. Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood Adv. 4(3), 530–538 (2020).Crossref, Medline, CAS, Google Scholar5. Özgür Yurttaş N, Eşkazan AE. Novel therapeutic approaches in chronic myeloid leukemia. Leuk. Res. 91, 106337 (2020).Crossref, Medline, Google Scholar6. Wylie AA, Schoepfer J, Jahnke W et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 543(7647), 733–737 (2017).Crossref, Medline, CAS, Google Scholar7. Schuld P, Grzesiek S, Schlotte J et al. Structural and biochemical studies confirming the mechanism of action of asciminib, an agent specifically targeting the ABL myristoyl pocket (STAMP). Blood. 136(Suppl. 1), 34–35 (2020).Crossref, Google Scholar8. Hughes TP, Mauro MJ, Cortes JE et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N. Engl. J. Med. 381(24), 2315–2326 (2019).Crossref, Medline, CAS, Google Scholar9. Rea D, Mauro MJ, Boquimpani C et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after ≥2 prior TKIs. Blood. doi:10.1182/blood.2020009984 (2021).Crossref, Google Scholar10. Cortes JE, Hughes TP, Mauro MJ et al. Asciminib, a first-in-class STAMP inhibitor, provides durable molecular response in patients (pts) with chronic myeloid leukemia (CML) harboring the T315I mutation: primary efficacy and safety results from a phase 1 trial. Blood. 136(Suppl. 1), 47–50 (2020).Crossref, Google Scholar11. Garcia-Gutiérrez V, Luna A, Alonso-Dominguez JM et al. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. Blood Cancer J. 11(2), 16 (2021).Crossref, Medline, Google Scholar12. Eşkazan AE. Asciminib in chronic myeloid leukemia: many questions still remain to be answered. Blood Cancer J. 11(4), 81 (2021).Crossref, Medline, Google Scholar13. Eide CA, Zabriskie MS, Savage Stevens SL et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell 36(4), 431–443.e5 (2019).Crossref, Medline, CAS, Google Scholar14. Cortes J, Lang F, Kim DW et al. Combination therapy using asciminib plus imatinib (IMA) in patients (PTS) with chronic myeloid leukemia (CML): results from a phase 1 study. HemaSphere. 3(S1), 397 (2019).Crossref, Google Scholar15. Mauro MJ, Kim DW, Cortes J et al. Combination of asciminib plus nilotinib (NIL) or dasatinib (DAS) in patients (PTS) with chronic myeloid leukemia (CML): Results from a phase 1 study. HemaSphere. 3(S1), 398–398 (2019).Crossref, Google Scholar16. Hall KH, Brooks A, Waller EK. Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib. Am. J. Hematol. 96(8), e293–e295 (2021).Crossref, Medline, CAS, Google Scholar17. Frontline asciminib combination in chronic phase CML (CMLXI) (2021). https://clinicaltrials.gov/ct2/show/NCT03906292Google Scholar18. Study of efficacy and safety of asciminib in combination with imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) (2021). https://clinicaltrials.gov/ct2/show/NCT03578367Google Scholar19. ABL001 for the treatment of chronic myeloid leukemia in patients who are on therapy with tyrosine kinase inhibitor (2021). https://clinicaltrials.gov/ct2/show/NCT04216563Google Scholar20. Asciminib in monotherapy for chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML) (2021). https://clinicaltrials.gov/ct2/show/NCT04666259Google Scholar21. PABL001 + dasatinib + prednisone in BCR-ABL+ B-ALL or CML (2021). https://clinicaltrials.gov/ct2/show/NCT03595917Google ScholarFiguresReferencesRelatedDetailsCited ByGuidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities5 September 2022 | International Journal of Hematology, Vol. 117, No. 1Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trialJorge E Cortes, Andreas Hochhaus, Naoto Takahashi, Richard A Larson, Ghayas C Issa, Felice Bombaci, Nicholas Ramscar, Sophie Ifrah & Timothy P Hughes16 December 2022 | Future Oncology, Vol. 18, No. 38Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting4 March 2022 | Expert Review of Hematology, Vol. 15, No. 2 Vol. 17, No. 36 eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 195 times History Received 14 September 2021 Accepted 15 September 2021 Published online 18 November 2021 Published in print December 2021 Information© 2021 Future Medicine LtdKeywordsABL myristoyl pocketasciminibchronic myeloid leukemiaT315Ityrosine kinase inhibitorFinancial & competing interests disclosureM Tiribelli has received speaker bureau and advisory board honoraria from Novartis, Bristol Myers Squibb, Incyte and Celgene outside the present study. AE Eşkazan has received advisory board honoraria from Novartis and Pfizer. AE Eşkazan has also received speaker bureau honoraria from Novartis, Bristol Myers Squibb and Pfizer outside the present study. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download